FTH1P3 and breast carcinoma: Breast cancer is one of the most common gynaecological malignancies for women and causes significant morbidity and mortality worldwide.2, 15, 16 Clinically, chemotherapy is the most effective assistant therapeutic method for the treatment of breast cancer.17 However, the occurrence of chemoresistance causes the poor prognosis, high recurrence rate and low 5‐year survival rate.18 In the present study, we investigate the role of lncRNA FTH1P3 in breast cancer paclitaxel resistance and explore the underlying mechanism for the drug resistance generation.